How patients obtain medical cannabis through licensed clinics and specialist prescribers.
German patients challenging the recent controversial changes to medical cannabis reimbursement via statutory health insurance (GKV) are facing lengthy battles across the country’s courts.
Thousands of Dutch patients are facing a 10-month supply gap for medically essential Bedrocan products, including varieties clinicians consider irreplaceable for children with treatment-resistant epilepsy.
Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.
Bedrocan, the Dutch medical cannabis stalwart thousands of patients rely on for their prescriptions, is now fighting to avoid collapse.
The imminent launch of the first new European cannabis-based pharmaceutical for over five years could not have been better timed, it seems.
Last month, the German government passed a controversial cost-saving law that saw tens of thousands of patients denied access medical cannabis to flower reimbursed through statutory health insurance (GKV).
Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
Germany has today voted to ban medical cannabis flower from its statutory health insurance scheme, in a controversial move critics say will have an outsized impact on the ‘seriously ill’.
Cannabis Health, the UK’s leading medical cannabis news and education platform, has announced the launch of two autumn events designed for healthcare professionals, prescribers, and industry operators working at the frontline of medical cannabis practice across Europe.
